SCHEDULE: State Street Reports 5.4% Stake in Cytomx Therapeutics

State Street Corporation has disclosed beneficial ownership of 5.4% of Cytomx Therapeutics' common stock as of June 30, 2026.

Summary

• State Street Corporation, through its subsidiaries, now beneficially owns 11,747,236 shares of Cytomx Therapeutics' common stock.
• This represents 5.4% of the total class of securities.
• The filing indicates shared voting power of 11,471,693 shares and shared dispositive power for all 11,747,236 shares.
• The reporting entity is State Street Corporation, a financial institution organized in Massachusetts.
• The filing is made under Rule 13d-1(b) of the Securities Exchange Act of 1934.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership percentage without indicating new strategic initiatives or significant financial performance changes.

Positives

• State Street Corporation's increased stake may signal confidence in Cytomx Therapeutics' long-term prospects.
• The filing provides transparency regarding significant institutional ownership.

Negatives

• The filing does not provide specific reasons for the change in beneficial ownership, leaving potential motivations open to interpretation.

Risks

• Potential for future changes in beneficial ownership by State Street Corporation or other large institutional investors could impact share price volatility.
• Concentration of ownership among a few large holders can sometimes lead to less liquid trading conditions.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or specific guidance regarding Cytomx Therapeutics' future performance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors like State Street Corporation, indicating their role as passive investors managing significant portfolios. This filing reflects a standard disclosure of holdings in Cytomx Therapeutics.

Stakeholder Impact

• Shareholders: Increased institutional ownership can sometimes lead to greater stock stability or influence on corporate actions.
• Creditors: No direct impact indicated by this filing.
• Employees: No direct impact indicated by this filing.
• Suppliers/Customers: No direct impact indicated by this filing.

Next Steps

• State Street Corporation will continue to hold and potentially adjust its beneficial ownership of Cytomx Therapeutics' common stock.
• Future filings will be made if ownership levels change significantly according to SEC regulations.

Key Dates

Keywords

Cytomx Therapeutics, State Street Corporation, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Securities Exchange Act